

CITATION REPORT

List of articles citing

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

DOI: 10.2337/dc15-0165
Diabetes Care, 2016, 39, 231-41.

Source: <https://exaly.com/paper-pdf/62655524/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
125	SUSTAIN-6: cardiovascular safety of a once-weekly GLP-1 receptor agonist. 2016 , 33, 266-268a		2
124	Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. 2016 , 68, 954-1013		171
123	A Plethora of GLP-1 Agonists: Decisions About What to Use and When. 2016 , 16, 120		13
122	Intestinal permeation enhancers for oral peptide delivery. 2016 , 106, 277-319		184
121	Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. 2016 , 12, 566-92		205
120	Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists. 2016 , 18, 7		2
119	Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 203-16	6.7	248
118	Cardiovascular safety and benefits of GLP-1 receptor agonists. 2017 , 16, 351-363		25
117	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. 2017 , 5, 251-260		206
116	Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1242-1251	6.7	137
115	Glucagon-like peptide-1 agonists for weight loss in people with obesity. 2017 , 5, 29-43		
114	Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment. 2017 , 56, 1381-1390		52
113	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. 2017 , 60, 1390-1399		32
112	Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. 2017 , 5, 341-354		189
111	Glycaemic control and weight loss with semaglutide in type 2 diabetes. 2017 , 5, 315-317		4
110	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. 2017 , 5, 355-366		180
109	Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. 2017 , 47, 266-280		44

108	Trends in GPCR drug discovery: new agents, targets and indications. 2017 , 16, 829-842	1046
107	Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics. 2017 , 1030, 185-227	25
106	Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. 2017 , 136, 849-870	279
105	GLP-1/glucagon receptor co-agonism for treatment of obesity. 2017 , 60, 1851-1861	84
104	Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. 2017 , 14, 1113-1131	4
103	Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146. 2017 , 281, 25-40	20
102	Semaglutide seems to be more effective the other GLP-1Ras. 2017 , 5, 505	18
101	The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease. 2016 , 7, 526	46
100	Semaglutide-the "" in the field of glucagon-like peptide-1 receptor agonists?. 2017 , 5, 475	7
99	Targeting GLP-1 receptor trafficking to improve agonist efficacy. 2018 , 9, 1602	88
98	Gut hormone polyagonists for the treatment of type 2 diabetes. 2018 , 100, 190-201	70
97	Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. 2018 , 18, 343-351	7
96	Semaglutide: First Global Approval. 2018 , 78, 275-284	32
95	Newer GLP-1 receptor agonists and obesity-diabetes. 2018 , 100, 61-67	29
94	Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells. 2018 , 55, 405-418	9
93	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. 2018 , 93, 217-239	57
92	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 508-519	6.7 25
91	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 610-619	6.7 69

90	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42		103
89	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 378-388	6.7	48
88	The mode and mechanism of action of once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes. 2018 , 30, S12-S18		0
87	GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. 2018 , 17, 157		60
86	Semaglutide once-weekly: improved efficacy with a new safety warning. 2018 , 11, 1061-1072		7
85	No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects. 2018 , 9, 1441-1456		6
84	Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2255-2263	6.7	39
83	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2210-2219	6.7	44
82	Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2238-2245	6.7	12
81	Are peptide conjugates the golden therapy against obesity?. 2018 , 238, R109-R119		16
80	MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. 2018 , 391, 2607-2618		149
79	Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2018 , 9, 576		18
78	The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. 2018 , 67, 1710-1719		50
77	Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis. 2018 , 9, 1533-1547		15
76	A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. 2018 , 14, 869-877		35
75	MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. 2018 , 84, 2325-2335		32
74	Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes. 2019 , 43, 136-145		26
73	The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. 2019 , 13, 2985-2996		6

72	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. 2019 , 98, 104-111	7
71	Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series. 2019 , 11, 219-224	14
70	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. 2019 , 20,	23
69	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. 2019 , 10, 1733-1752	26
68	Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?. 2019 , 394, 4-6	1
67	Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. 2019 , 17, 377-387	6
66	Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. 2019 , 16, 2278-2295	27
65	Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy. 2019 , 13, 731-738	14
64	Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. 2019 , 20, 816-828	54
63	Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists. 2019 , 42, 957-971	11
62	Semaglutide as a promising antiobesity drug. 2019 , 20, 805-815	33
61	Modeling the impact of preplanned dose titration on delayed response. 2019 , 29, 287-305	1
60	Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. 2019 , 45, 102-109	10
59	Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 355-364	6.7 20
58	Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta-analysis. 2020 , 3, e00100	2
57	Incretin therapy for diabetes mellitus type 2. 2020 , 27, 2-10	11
56	Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy. 2020 , 11, 319-330	3
55	A review of GLP-1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once-weekly agents. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020 , 45 Suppl 1, 17-27	2.2 16

54	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 analyses. 2020 , 10, e037883		3
53	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. 2020 , 18, 322		1
52	Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches. 2020 , 9,		14
51	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. 2020 , 8,		11
50	Semaglutide injection for the treatment of adults with type 2 diabetes. 2020 , 13, 675-684		3
49	Efficacy and safety of once-monthly efglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1176-1186	6.7	12
48	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis. 2020 , 9, e015323		6
47	Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 136-146	6.7	5
46	Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. 2021 , 46, 101153		2
45	Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study. 2021 , 12, 943-954		5
44	Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects. 2021 , 60, 1171-1185		3
43	Proglucagon-Derived Peptides as Therapeutics. 2021 , 12, 689678		7
42	Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. <i>Diabetes Care</i> , 2021 , 44, 1433-1442	14.6	30
41	Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists. 2021 , 30, 1016-1027		1
40	Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis. 2021 , 9,		1
39	Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?. 2021 ,		3
38	Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. 2021 , 12, 2783-2794		1
37	Anti-diabetic drugs and weight loss in patients with type 2 diabetes. 2021 , 171, 105782		9

36	KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats. 2021 , 53, 101282		4
35	Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). <i>Diabetes Care</i> , 2021 , 44, 765-773	14.6	36
34	Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco mouse. 2017 , 12, e0179856		12
33	SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. 2018 , 6, 129		
32	Clinical potential of treatment with semaglutide in type 2 diabetes patients. 2019 , 8, 212585		2
31	Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis. 2021 , 42, 101213		5
30	Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.. 2022 , 1		4
29	Efficient estimation of the efficacy and safety endpoints for clinical trials with preplanned dose titrations. 1-30		
28	Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.. 2022 , 15, 155-163		1
27	Is polypharmacy the future for pharmacological management of obesity?. 2022 , 23, 100322		1
26	Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.. 2022 , 13, 831364		0
25	Glucagon-Like Peptide 1 Receptor Agonists - Potential Game Changers in the Treatment of Glaucoma?. <i>Frontiers in Neuroscience</i> , 2022 , 16, 824054	5.1	1
24	Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	1
23	̳nAChR agonist GTS-21 engages the GLP-1 incretin hormone axis to lower levels of blood glucose in db/db mice.. <i>Diabetes, Obesity and Metabolism</i> , 2022 ,	6.7	0
22	Clinical review of subcutaneous semaglutide for obesity.. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021 ,	2.2	1
21	Image_1.tif. 2018 ,		
20	Image_2.tif. 2018 ,		
19	Image_3.tif. 2018 ,		

18 Table_1.DOCX. 2018,

17 Table_2.DOCX. 2018,

16 Table_3.DOCX. 2018,

15 Table_4.DOCX. 2018,

14 Table_5.DOCX. 2018,

13 Table_6.DOCX. 2018,

12 Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis.. *BMC Endocrine Disorders*, 2022, 22, 113 3.3 1

11 Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 2022, 16, 102511 8.9 0

10 Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. 0

9 Semaglutide ameliorates lipopolysaccharide-induced acute lung injury through inhibiting HDAC5-mediated activation of NF- κ B signaling pathway. 2022, 41, 096032712211259 0

8 Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. 13, 0

7 Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis. 2022, 100456 0

6 LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. 2022, 3

5 The importance of estradiol for body weight regulation in women. 13, 0

4 Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: an Australian perspective on guidelines and the global evidence. 0

3 Semaglutide in Obesity: Unmet Needs in Men. 0

2 GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. 2023, 24, 587-597 0

1 Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. 2023, 365-396 0

